Helping biotech teams design IND-ready biomarker strategies, de-risk clinical development, and move programs forward with confidence.
I work with biotech teams preparing for IND or early clinical development to design biomarker and translational strategies that hold up in the clinic.
My experience includes leading translational medicine and biomarker strategy at Karyopharm Therapeutics and Omega Therapeutics across oncology and RNA therapeutic programs.
Transforming groundbreaking science into viable therapies demands more than ambition—it requires regulatory experience, biomarker intelligence, and a deep understanding of clinical trial intricacies.
At BioTargeted Solutions, we empower biotech and pharmaceutical pioneers to expedite IND approvals, craft biomarker-driven clinical strategies, and navigate the complexities of drug development with confidence.
Services
Drug Development & IND Strategy
Guiding companies through regulatory submissions, optimizing IND packages, and streamlining approval pathways.
Example Strategies:
Exploratory IND: Rethinking the Clinical Drug Development Strategy
Biomarker Plan Development
Designing biomarker-driven clinical trials to enhance patient selection, improve efficacy, and increase trial success rates.
Example Exploratory Endpoints:
Use of ctDNA for Early-Stage Solid Tumor Drug Development
Plasma ctDNA Response Is an Early Marker of Treatment Effect
Recent Experience
- Led biomarker strategy for IND-stage oncology and RNA therapeutic programs
- Designed ctDNA and translational endpoints for early clinical trials
- Supported IND-enabling studies and regulatory positioning
- Advised biotech startups on biomarker integration and clinical strategy
Book a Free 30-Min Strategy Call
Discuss your IND plan, biomarker approach, or translational strategy and identify key risks before they become delays.
[Schedule a Consultation]
